BioSpace News Archive

Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point.

DSS, Inc. announced today the distribution date for the previously announced stock dividend of Impact BioMedical Inc. DSS Inc. shareholders of record on July 10, 2023 will be entitled to four (4) shares of Impact Biomedical Inc. for every one (1) share of DSS to be distributed on August 8, 2023.

Smirta is pleased to announce that OneOncology has selected Smirta as a preferred vendor to provide Smirta’s OncoSmart® oncology infusion schedule optimization platform to the OneOncology network of physician practices.

Florida Cancer Specialists & Research Institute, LLC (FCS) physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with Extensive-Stage Small Cell Lung Cancer.

AMIRO (“the Company”), a leading beauty and skincare technology brand, is thrilled to announce that its research facility, AMIRO LAB , has successfully obtained the Qualified Testing Location (QTL) certification after a comprehensive audit conducted by SGS.

Pattern Bioscience, Inc. today announced that it was named the winner of the Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine (ADLM, formerly known as AACC).

COMPASS Pathways plc, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it will release financial results for the second quarter 2023, and provide an update on recent business developments on August 3, 2023.

G1 Therapeutics, Inc. (Nasdaq: GTHX) today announced the publication of real world outcomes data from published and new unpublished studies showing the potential of trilaciclib to reduce single and multilineage myelosuppressive events associated with chemotherapy, cytopenia-related healthcare utilization, and hospitalizations in adults being treated for extensive stage small cell lung cancer (ES-SCLC).

Globus Medical, Inc. announced the commercial launch of the MARVEL™ Growing Rod System, which is designed for pediatric patients with early onset scoliosis to obtain and maintain correction while allowing for growth through minimally invasive distraction.

Mustang Bio, Inc. today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc.